HA-1H TCR-transduced T cells

HA-1H TCR-transduced T cells are autologous or allogeneic T cells that have been genetically modified ex vivo to express a T cell receptor (TCR) specific for the minor histocompatibility antigen HA-1H. This antigen is presented by HLA-A*02:01 and is selectively restricted to hematopoietic cells. The engineered T cells are intended to induce selective graft-versus-leukemia (GVL) effects after allogeneic stem cell transplantation by targeting residual leukemic cells without causing significant graft-versus-host disease (GVHD). The therapeutic objective is to enhance immune attack on malignant hematopoietic cells in patients with hematologic malignancies, especially acute myeloid leukemia (AML). Most advanced clinical studies have used donor-derived cytomegalovirus (CMV) or Epstein–Barr virus (EBV)-specific T cells that are transduced with the HA-1H-specific TCR, allowing for both anti-viral and anti-leukemic function. Early trials have focused on safety and feasibility, showing absence of severe toxicity or GVHD, but clinical efficacy remains limited.

Other names

HA-1H TCR T cellsHA1H TCR T cellsHA 1H TCR T cellsHA-1H TCR-engineered T cellsHA1H TCR-engineered T cellsHA 1H TCR-engineered T cells